The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study
Open accessAbstract
Background Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72.Methods In this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used mixed effects models to explore differences in age at onset, age at death, and disease duration between genetic groups and individual mutations. We also assessed correlations between the age at onset and at death of each individual and the age at onset and at death of their parents and the mean age at onset and at death of their family members. Lastly, we used mixed effects models to investigate the extent to which variability in age at onset and at death could be accounted for by family membership and the specific mutation carried.Findings Data were available from 3403 individuals from 1492 families: 1433 with C9orf72 expansions (755 families), 1179 with GRN mutations (483 families, 130 different mutations), and 791 with MAPT mutations (254 families, 67 different mutations). Mean age at symptom onset and at death was 49·5 years (SD 10·0; onset) and 58·5 years (11·3; death) in the MAPT group, 58·2 years (9·8; onset) and 65·3 years (10·9; death) in the C9orf72 group, and 61·3 years (8·8; onset) and 68·8 years (9·7; death) in the GRN group. Mean disease duration was 6·4 years (SD 4·9) in the C9orf72 group, 7·1 years (3·9) in the GRN group, and 9·3 years (6·4) in the MAPT group. Individual age at onset and at death was significantly correlated with both parental age at onset and at death and with mean family age at onset and at death in all three groups, with a stronger correlation observed in the MAPT group (r=0·45 between individual and parental age at onset, r=0·63 between individual and mean family age at onset, r=0·58 between individual and parental age at death, and r=0·69 between individual and mean family age at death) than in either the C9orf72 group (r=0·32 individual and parental age at onset, r=0·36 individual and mean family age at onset, r=0·38 individual and parental age at death, and r=0·40 individual and mean family age at death) or the GRN group (r=0·22 individual and parental age at onset, r=0·18 individual and mean family age at onset, r=0·22 individual and parental age at death, and r=0·32 individual and mean family age at death). Modelling showed that the variability in age at onset and at death in the MAPT group was explained partly by the specific mutation (48%, 95% CI 35-62, for age at onset; 61%, 47-73, for age at death), and even more by family membership (66%, 56-75, for age at onset; 74%, 65-82, for age at death). In the GRN group, only 2% (0-10) of the variability of age at onset and 9% (3-21) of that of age of death was explained by the specific mutation, whereas 14% (9-22) of the variability of age at onset and 20% (12-30) of that of age at death was explained by family membership. In the C9orf72 group, family membership explained 17% (11-26) of the variability of age at onset and 19% (12-29) of that of age at death.Interpretation Our study showed that age at symptom onset and at death of people with genetic frontotemporal dementia is influenced by genetic group and, particularly for MAPT mutations, by the specific mutation carried and by family membership. Although estimation of age at onset will be an important factor in future pre-symptomatic therapeutic trials for all three genetic groups, our study suggests that data from other members of the family will be particularly helpful only for individuals with MAPT mutations. Further work in identifying both genetic and environmental factors that modify phenotype in all groups will be important to improve such estimates.Funding UK Medical Research Council, National Institute for Health Research, and Alzheimer's Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“F-FTD is rare, with only hundreds of mutation carriers known to exist worldwide.12”
From Temporal order of clinical and biomarker changes in familial frontotemporal dementia (2022) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, in GRN, familial age of onset only explains 14% of the variability in individual age at symptom onset.12”
From Temporal order of clinical and biomarker changes in familial frontotemporal dementia (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although people with mutations causing frontotemporal lobar degeneration usually have frontotemporal dementia or a related clinical syndrome (eg, corticobasal syndrome or progressive supranuclear palsy presenting as Richardson syndrome), some individuals have genetic frontotemporal lobar degeneration with another phenotype.13”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citationCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Self-citationMutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration
Gass, J., Cannon, A., Mackenzie, I. R., Boeve, B., Baker, M., Adamson, J., Crook, R., Melquist, S., Kuntz, K., Petersen, R., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl241 · Cited by 580
Self-citationRohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationThe heritability and genetics of frontotemporal lobar degeneration
Rohrer, J. D., Guerreiro, R., Vandrovcova, J., Uphill, J., Reiman, D., Beck, J., Isaacs, A. M., Authier, A., Ferrari, R., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bf997a · Cited by 536
Self-citationSymptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502
Self-citationLe Ber, I., Camuzat, A., Hannequin, D., Pasquier, F., Guedj, E., Rovelet-Lecrux, A., Hahn-Barma, V., van der Zee, J., Clot, F., Bakchine, S., et al. (2008) · Brain · doi:10.1093/brain/awn012 · Cited by 352
Self-citationProgranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury
Martens, L. H., Zhang, J., Barmada, S. J., Zhou, P., Kamiya, S., Sun, B., Min, S.-W., Gan, L., Finkbeiner, S., Huang, E. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63113 · Cited by 315
Warren, J. D., Rohrer, J. D., & Rossor, M. N. (2013) · BMJ · doi:10.1136/bmj.f4827 · Cited by 292
Self-citationvan Blitterswijk, M., DeJesus-Hernandez, M., Niemantsverdriet, E., Murray, M. E., Heckman, M. G., Diehl, N. N., Brown, P. H., Baker, M. C., Finch, N. A., Bauer, P. O., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70210-2 · Cited by 274
Self-citation
Cited by
Root, J., Merino, P., Nuckols, A., Johnson, M., & Kukar, T. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105360 · Cited by 238
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Self-citationProgranulin as a therapeutic target in neurodegenerative diseases
Rhinn, H., Tatton, N., McCaughey, S., Kurnellas, M., & Rosenthal, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.015 · Cited by 208
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Self-citationC9ORF72: What It Is, What It Does, and Why It Matters
Smeyers, J., Banchi, E.-G., & Latouche, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661447 · Cited by 168
Metadata
- Authors
- Moore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., Mead, S., Bocchetta, M., Boeve, B. F., Knopman, D. S., Graff-Radford, N. R., Forsberg, L. K., Rademakers, R., Wszolek, Z. K., van Swieten, J. C., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Snowden, J. S., Saxon, J., Jones, M., Pickering-Brown, S., Le Ber, I., Camuzat, A., Brice, A., Caroppo, P., Ghidoni, R., Pievani, M., Benussi, L., Binetti, G., Dickerson, B. C., Lucente, D., Krivensky, S., Graff, C., Öijerstedt, L., Fallström, M., Thonberg, H., Ghoshal, N., Morris, J. C., Borroni, B., Benussi, A., Padovani, A., Galimberti, D., Scarpini, E., Fumagalli, G. G., Mackenzie, I. R., Hsiung, G.-Y. R., Sengdy, P., Boxer, A. L., Rosen, H., Taylor, J. B., Synofzik, M., Wilke, C., Sulzer, P., Hodges, J. R., Halliday, G., Kwok, J., Sanchez-Valle, R., Lladó, A., Borrego-Ecija, S., Santana, I., Almeida, M. R., Tábuas-Pereira, M., Moreno, F., Barandiaran, M., Indakoetxea, B., Levin, J., Danek, A., Rowe, J. B., Cope, T. E., Otto, M., Anderl-Straub, S., de Mendonça, A., Maruta, C., Masellis, M., Black, S. E., Couratier, P., Lautrette, G., Huey, E. D., Sorbi, S., Nacmias, B., Laforce, R., Tremblay, M.-P. L., Vandenberghe, R., Damme, P. V., Rogalski, E. J., Weintraub, S., Gerhard, A., Onyike, C. U., Ducharme, S., Papageorgiou, S. G., Ng, A. S. L., Brodtmann, A., Finger, E., Guerreiro, R., Bras, J., Rohrer, J. D., Heller, C., Convery, R. S., Woollacott, I. O., Shafei, R. M., Graff-Radford, J., Jones, D. T., Dheel, C. M., Savica, R., Lapid, M. I., Baker, M., Fields, J. A., Gavrilova, R., Domoto-Reilly, K., Poos, J. M., Van der Ende, E. L., Panman, J. L., Donker Kaat, L., Seelaar, H., Richardson, A., Frisoni, G., Mega, A., Fostinelli, S., Chiang, H.-H., Alberici, A., Arighi, A., Fenoglio, C., Heuer, H., Miller, B., Karydas, A., Fong, J., João Leitão, M., Santiago, B., Duro, D., Ferreira, C., Gabilondo, A., De Arriba, M., Tainta, M., Zulaica, M., Ferreira, C., Semler, E., Ludolph, A., Landwehrmeyer, B., Volk, A. E., Miltenberger, G., Verdelho, A., Afonso, S., Tartaglia, M. C., Freedman, M., Rogaeva, E., Ferrari, C., Piaceri, I., Bessi, V., Lombardi, G., St-Onge, F., Doré, M.-C., Bruffaerts, R., Vandenbulcke, M., Van den Stock, J., Mesulam, M. M., Bigio, E., Koros, C., Papatriantafyllou, J., Kroupis, C., Stefanis, L., Shoesmith, C., Robertson, E., Coppola, G., Da Silva Ramos, E. M., & Geschwind, D.
- Affiliations
- UCL Queen Square Institute of Neurology (GB)
- London School of Hygiene & Tropical Medicine (GB)
- University of Pennsylvania (US)
- University College London (GB)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- Erasmus MC (NL)
- Salford Royal NHS Foundation Trust (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- Harvard University (US)
- Karolinska University Hospital (SE)
- Washington University in St. Louis (US)
- University of Brescia (IT)
- University of Milan (IT)
- University of British Columbia (CA)
- University of California, San Francisco (US)
- German Center for Neurodegenerative Diseases (DE)
- The University of Sydney (AU)
- Hospital Clínic de Barcelona (ES)
- Unidade Local de Saúde de Coimbra (PT)
- Centro de Neurociências e Biologia Celular (PT)
- Instituto de Salud Carlos III (ES)
- Ludwig-Maximilians-Universität München (DE)
- University of Cambridge (GB)
- Universität Ulm (DE)
- University of Lisbon (PT)
- Sunnybrook Health Science Centre (CA)
- Centre Hospitalier Universitaire de Limoges (FR)
- Columbia University (US)
- Don Carlo Gnocchi Foundation (IT)
- University of Florence (IT)
- Hôpital de l'Enfant-Jésus (CA)
- Universitair Ziekenhuis Leuven (BE)
- Northwestern University (US)
- University of Manchester (GB)
- Johns Hopkins University (US)
- McGill University Health Centre (CA)
- National and Kapodistrian University of Athens (GR)
- National Neuroscience Institute (SG)
- Florey Institute of Neuroscience and Mental Health (AU)
- Western University (CA)
- Van Andel Institute (US)
- Corresponding author
- Rohrer, Jonathan D
- ORCID
- Moore, Katrina M
- Nicholas, Jennifer
- Grossman, Murray
- McMillan, Corey T
- Irwin, David J
- Massimo, Lauren
- Warren, Jason D
- Fox, Nick C
- Rossor, Martin N
- Mead, Simon
- Bocchetta, Martina
- Boeve, Bradley F
- Knopman, David S
- Forsberg, Leah K
- Rademakers, Rosa
- Jiskoot, Lize C
- Meeter, Lieke H
- Dopper, Elise GP
- Snowden, Julie S
- Saxon, Jennifer
- Jones, Matthew
- Pickering-Brown, Stuart
- Brice, Alexis
- Caroppo, Paola
- Ghidoni, Roberta
- Pievani, Michela
- Benussi, Luisa
- Binetti, Giuliano
- Dickerson, Bradford C
- Lucente, Diane
- Graff, Caroline
- Öijerstedt, Linn
- Ghoshal, Nupur
- Morris, John C
- Borroni, Barbara
- Benussi, Alberto
- Padovani, Alessandro
- Galimberti, Daniela
- Scarpini, Elio
- Fumagalli, Giorgio G
- Mackenzie, Ian R
- Hsiung, Ging-Yuek R
- Boxer, Adam L
- Synofzik, Matthis
- Wilke, Carlo
- Sulzer, Patricia
- Hodges, John R
- Halliday, Glenda
- Kwok, John
- Lladó, Albert
- Santana, Isabel
- Almeida, Maria Rosário
- Levin, Johannes
- Danek, Adrian
- Rowe, James B
- Cope, Thomas E
- Otto, Markus
- Maruta, Carolina
- Masellis, Mario
- Black, Sandra E
- Couratier, Philippe
- Huey, Edward D
- Sorbi, Sandro
- Nacmias, Benedetta
- Laforce, Robert
- Vandenberghe, Rik
- Damme, Philip Van
- Rogalski, Emily J
- Gerhard, Alexander
- Onyike, Chiadi U
- Ducharme, Simon
- Papageorgiou, Sokratis G
- Brodtmann, Amy
- Finger, Elizabeth
- Guerreiro, Rita
- Rohrer, Jonathan D
- Heller, Carolin
- Convery, Rhian S
- Woollacott, Ione OC
- Shafei, Rachelle M
- Jones, David T
- Savica, Rodolfo
- Lapid, Maria I
- Baker, Matt
- Fields, Julie A
- Poos, Jackie M
- Panman, Jessica L
- Seelaar, Harro
- Richardson, Anna
- Frisoni, Giovanni
- Mega, Anna
- Fostinelli, Silvia
- Alberici, Antonella
- Arighi, Andrea
- Fenoglio, Chiara
- Heuer, Hilary
- Miller, Bruce
- Fong, Jamie
- Santiago, Beatriz
- Duro, Diana
- Ferreira, Carlos
- Gabilondo, Alazne
- Tainta, Mikel
- Zulaica, Miren
- Ferreira, Catarina
- Semler, Elisa
- Volk, Alexander E
- Verdelho, Ana
- Tartaglia, Maria Carmela
- Freedman, Morris
- Rogaeva, Ekaterina
- Ferrari, Camilla
- Piaceri, Irene
- Bessi, Valentina
- Lombardi, Gemma
- Bruffaerts, Rose
- Vandenbulcke, Mathieu
- Mesulam, M Marsel
- Bigio, Eileen
- Koros, Christos
- Papatriantafyllou, John
- Stefanis, Leonidas
- Geschwind, Daniel
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 19
- Issue
- 2
- Pages
- 145-156
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC7007771
- OpenAlex
- W2993046104
- Cited by
- 313
- References
- 39
- Citations by year
- 2026: 33 · 2025: 49 · 2024: 51 · 2023: 53 · 2022: 48 · 2021: 54 · 2020: 24
- FWCI
- 21.28
- Type
- journal article
- Language
- en
- Update notices
- erratum (2020-02-01)
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Iris (University of Trento) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- DZNE Pub (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Apollo
- Funders
- National Institute on Aging
- Medical Research Council
- National Institute of Neurological Disorders and Stroke
- National Institute for Health and Care Research
- Alzheimer's Drug Discovery Foundation
- Association for Frontotemporal Degeneration
- EU Joint Programme – Neurodegenerative Disease Research
- Canadian Institutes of Health Research
- National Institutes of Health
- Ontario Ministry of Economic Development and Innovation
- Novartis
- Bundesministerium für Bildung und Forschung
- Roche
- Heart and Stroke Foundation of Canada
- Stichting Dioraphte
- Alzheimer's Society
- Stockholm läns landsting
- National Health and Medical Research Council
- Eli Lilly and Company
- Agence Nationale de la Recherche
- Genentech
- ZonMw
- UCLH Biomedical Research Centre
- UK Dementia Research Institute
- Alzheimer's Disease Research Center, Emory University
- Fédération pour la Recherche sur le Cerveau
- GE Healthcare
- Institut de France
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Biogen
- Hjärnfonden
- AbbVie
- Karolinska Institutet
- Centre Hospitalier Universitaire de Nice
- Fondation Roger de Spoelberch
- Alzheimerfonden
- Wellcome Trust
- UCB
- Janssen Pharmaceuticals
- Ontario Brain Institute
- Fondation Brain Canada
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- frontotemporal dementia, genetic frontotemporal dementia, age at symptom onset, age at death, disease duration, GRN mutations, MAPT mutations, C9orf72 repeat expansion, familial aggregation, family history (medicine), heritability, genotype-phenotype correlation
- MeSH terms
- C9orf72 Protein, Progranulins, Adult, Aged, Aged, 80 and over, Family, Female, Humans, Male, Middle Aged, Mutation, Phenotype, Retrospective Studies, Cohort Studies, tau Proteins, Age of Onset, Disease Progression, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. https://app.cochat.ai/papers/10.1016/s1474-4422(19)30394-1
- The paper
- Moore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., Mead, S., Bocchetta, M., Boeve, B. F., Knopman, D. S., Graff-Radford, N. R., Forsberg, L. K., Rademakers, R., Wszolek, Z. K., van Swieten, J. C., . . . Geschwind, D. (2020). Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(19)30394-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.